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Objective: In this longitudinal study, we monitored two large groups of multiple sclerosis
(MS) patients and healthy controls (HC) for 2 years, with the aim of comparing their
neuropsychological profile over time.
Method: Three hundred and twenty-two patients with MS and 303 HC were
administered the Brief Repeatable Battery of Neuropsychological tests (BRB-N);
neuropsychiatric measures were also administered. Two follow-ups were scheduled at
1 and 2 years, respectively.
Results: A linear mixed model (LMM) with random intercept was run by considering
participants’ performance on each test of the BRB-N at the three assessment points
(baseline and follow-ups) as the within-subjects variable, and group (patients and
controls) as the between-subjects factor. The interaction term was statistically significant
for the tests: Symbol Digit Modalities test (SDMT) (p = 0.044), Paced Auditory Serial
Addition test (PASAT) (p = 0.011) and Word List Generation (WLG) (p < 0.001), whereas
for the PASAT-3 approached statistical significance (p = 0.05). In addition, a LMM
with random intercept was also run by identifying three groups (controls, relapsing-
remitting course of MS (i.e. RR-MS), and prog-MS). The interaction term was statistically
significant for: PASAT-3 (p = 0.017), PASAT-2 (p = 0.0026), and WLG (p = 0.0022).
Conclusions: Our results corroborate on a very large scale evidence that the abilities
tapped by the tasks SDMT, PASAT and WLG are particularly sensitive to MS, and further
extend this issue by showing that these abilities are likely to be more sensitive than
others to the progression of the disease, as compared to HC.
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INTRODUCTION
Neurological and neuropsychiatric conditions are often
characterized by significant deficits that reduce significantly
patients’ abilities and their overall quality of life (Borghi et al.,
2013; Cavallo et al., 2013a,b). Multiple Sclerosis (MS) is a
chronic neurodegenerative condition characterized by white
matter lesions, axonal damage, and cerebral atrophy (Kornek
and Lassmann, 2003; Bermel and Bakshy, 2006) and frequently
associated with psychological problems (Ostacoli et al., 2013).
Cognitive deficit is a frequent clinical feature of MS, ranging
from 30% to 70% of patients (Rao et al., 1991; Borghi et al.,
2013). MS negatively affects various cognitive abilities such as
speed of processing, attention, new learning, executive functions,
and memory (DeLuca et al., 2004; Bodling et al., 2012; Borghi
et al., 2013). Cognitive deficits do not imply only problems in
performing accurately neuropsychological tests, but it is typically
related to patient’s reduced functional status, and has a serious
impact on patients’ quality of life (Kalmar et al., 2008; Fernández
et al., 2011).
An important issue pertains to the possible decline of patients’
neuropsychological abilities over time, as compared to healthy
controls (HC). In the last decade, some studies have started to
tackle this substantial issue. In one of the first studies, Piras
et al. (2003) recruited 12 patients affected by relapsing-remitting
MS, to monitor disease evolution, cognitive dysfunction and
cerebral lesion burden over 8.5 years. Their results showed the
presence of mild cognitive impairment in MS, mainly related
to a diminished information processing ability over time. In
addition, magnetic resonance imaging (MRI) lesions did not
correlate with the decline of cognitive abilities. A few years
later, Camp et al. (2005) performed a multi-center European
study involving an overall size of 99 patients affected by
primary progressive MS, with the aim of investigating cognitive
and MRI changes over 2 years. Their results did not show
the presence of a significant decline of neuropsychological
abilities over time, and only a very weak relation between
neuropsychological and structural neuroimaging measures was
found. Huijbregts et al. (2006) included in their study 30
secondary-progressive MS patients, 25 primary-progressive MS
patients, and 33 controls and investigated a 2-year follow-
up of neuropsychological performance on the Brief Repeatable
Battery of Neuropsychological tests (Rao et al., 1990). Their
results indicated that both progressive MS did not show a
learning effect on the Symbol Digit Modalities Test (SDMT)
and the Paced Auditory Serial Addition Test (PASAT) as
compared to controls, indicating that performance on tasks
requiring multiple abilities such as visuo-spatial ability and
processing speed (for SDMT) or working memory and
processing speed (for PASAT), is most likely to decline over
time.
More recently, Denney et al. (2008) recruited 24 MS patients
and 25 HC and monitored their neuropsychological profile over
a 3-year period. They showed that patients’ performance on
measures of speed of processing declined significantly over time,
as compared to the control group, whereas other domains such as
problem-solving abilities or verbal memory remained relatively
stable during the course of the study. A similar pattern of results
was recently shown byHankomäki et al. (2014). In another recent
study, Loitfelder et al. (2014) recruited 13MS patients and 15 HC
who underwent MRI including functional magnetic resonance
imaging (fMRI) and neuropsychological exams at baseline and at
follow-up (median: 20months): from a neuropsychological point
of view, their results showed that cognitive abilities remained
largely stable in the patients over time. Very recently, Nygaard
et al. (2015) investigated neuropsychological progression over
1 year in relapsing-remitting MS patients (N = 73) and
matched HC (n = 61). Patients were divided into those showing
‘‘evidence of disease activity’’ or showing ‘‘no evidence of disease
activity’’. While the two groups had similar disability levels
at baseline, they differed in their level of disability at follow-
up. Regarding the domain of cognition, both patients group
were stable. Lastly, Van Schependom et al. (2015) collected
neuropsychological data on N = 514 MS patients using the
Neuropsychological Screening Battery for MS and the SDMT.
Information processing speed was the domain most widely
affected in MS patients, and also the first cognitive ability to be
compromised in MS.
At this point in time, no studies have investigated changes
over time in neuropsychological abilities in a very large
group of MS patients, as compared to a very large group
of HC. In addition, little is known about the evolution of
the neuropsychological profile in progressive MS patients, as
compared to relapsing-remitting MS patients, and HC. Thus,
in the present prospective longitudinal study we monitored
two very large groups of MS patients (N = 322) and HC
(N = 303) for 2 years, with two aims: (1) investigating
the changes in neuropsychological abilities in MS patients
as compared to HC to differentiate what is normal decline
over time and what is MS related decline; and (2) detecting
possible differences over time in the neuropsychological
profile of different subgroups of patients affected by different
courses of the disease (relapsing-remitting vs. progressive
course of MS).
MATERIALS AND METHODS
A detailed presentation of the methods of this study has been
already reported in an our previous article aimed at investigating
the determinants of cognitive impairment in MS (Borghi et al.,
2013).
Participants
Three hundred and twenty-two patients with MS (97 males
and 225 females) were consecutively recruited from May 2010
to June 2012 from the CReSM (Regional Reference Center for
Multiple Sclerosis, affiliated with the University Hospital ‘‘San
Luigi Gonzaga’’ of Orbassano, Italy), an Italian reference center
for the diagnosis and treatment of patients with MS. All of the
patients underwent detailed biological and clinical investigations,
and received a diagnosis of MS, according to the standard
International criteria (Polman et al., 2011), by neurologists
expert in the diagnosis of MS. Patients with possible MS or
clinically isolated syndrome were not included in the study. More
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precisely, 89% of the patients suffered from a relapsing-remitting
course of the disease, while the others were characterized by a
progressive course of the condition.
Inclusion criteria were as follows: definite diagnosis of
MS according to the standard International criteria (Polman
et al., 2011); more than 18 years old; fluent Italian speakers.
Patients under high dosage of corticosteroids at the time of the
beginning of the study were temporarily excluded, and they were
administered the neuropsychological battery 1 month after the
interruption of the drug treatment. At the time of enrolment,
53% of patients were under immunomodulatory therapy; 12%
of patients under immunosuppressive therapy; 18% of patients
under monoclonal antibodies therapy; and 17% of patients were
not taking any medication. Exclusion criteria were as follows:
presence of severe psychiatric disorders such as psychosis or
bipolar disorder; presence of severe medical conditions other
than MS such as diabetes, stroke or traumatic brain injury; drug
or alcohol abuse; suicide attempts; overt dementia; and serious
eye disorders (such as diplopia).
Three hundred and three HC (93males and 210 females) were
recruited among the health professionals working at the same
hospital and among caregivers of patients admitted to different
hospital departments. None of the controls were consanguineous
of MS patients included in the present research project. A
clinical interview based on Green (2000) allowed us to rule out
in our control group the presence of significant neurological
or psychiatric disorders, of alcohol and drug abuse, or of
other relevant clinical conditions. Informed written consent was
obtained from all of the participants, in accordance with the
Declaration of Helsinki. This study was granted approval by the
Research Ethics Committee of the ‘‘San Luigi Gonzaga’’ Hospital
Medical School of Orbassano, Turin (Italy).
Procedure
The participants were administered the neuropsychiatric and
neuropsychological measures detailed below at the University
Hospital ‘‘San Luigi Gonzaga’’ of Orbassano (Italy) by expert
clinicians (MB, SC, FS).
Neuropsychiatric Measures
The participants were administered the following two measures:
the Hospital Anxiety and Depression Scale (HADS; Zigmond and
Snaith, 1983), a 14-item self-assessment scale that provides a
valid and reliable measure of severity of anxiety and depression;
and the Fatigue Severity Scale (FSS; Krupp et al., 1989), a
9-item one-dimensional questionnaire assessing the severity
of fatigue. Lastly, patients with MS received a score from
their neurologists on the Expanded Disability Status Scale
(EDSS; Kurtzke, 1983), to monitor their level of disability
presented at the time of the current neuropsychological
assessment.
Neuropsychological Measures
All of the participants were administered the Brief Repeatable
Battery of Neuropsychological Tests (BRB-N) for Multiple
Sclerosis (Rao et al., 1990), a neuropsychological battery sensitive
to the cognitive deficits that typically characterize MS. The
BRB-N encompasses the following tests: the Selective Reminding
Test (SRT), a test for verbal memory that provides measurement
of learning and delayed recall capacity. It yields three different
scores: the SRT-Long Term Storage (SRT-LTS), that provides
a measure of the storage capacity in long-term memory; the
SRT-Consistent Long Term Retrieval (SRT-CLTR), that provides
a measure of the consistency of the recovery in long-term
memory; the SRT-Delayed (SRT-D) a delayed recall of the
words of the previously learned. SPART, a test of learning
and delayed recall of visuo-spatial items. It yields two scores:
the SPART immediate recall score, and the SPART delayed
recall score. SDMT, a test of attention and of speed of
information processing. PASAT, that assesses the speed of
information processing, the working memory, and the sustained
attention. It encompasses two separate sub-tests (PASAT-2
and PASAT-3) in which the interval between two consecutive
items changes (2 or 3 s, respectively). Finally, Word List
Generation (WLG), a semantic verbal fluency task. For all
of the BRB-N tasks, higher scores mean better performance.
Furthermore, an additional cognitive measure was administered
to all of the participants at the beginning of the study:
the Brief Intelligence Test (Test di Intelligenza Breve, or
TIB; Colombo et al., 2002), functionally equivalent to the
National Adult Reading Test (Nelson, 1982), a well-established
measure aiming at estimating the pre-morbid Intelligence
Quotient.
Each participant was administered the BRB-N three times: at
the beginning of the study (T0), after 1 year (T1), and after 2 years
(T2). In order to minimize practice effects, two parallel versions
of the BRB-N were used: half of the participants started with
version A, then were administered version B at the 1-year follow-
up, and lastly were administered version A again at the 2-year
follow-up (i.e., A-B-A), whereas half of the participants did the
other way around (i.e., B-A-B). In doing so, the same version of
the neuropsychological battery was repeated by each participant
only after 2 years.
As in our previous study (Borghi et al., 2013), to define
the construct of ‘‘cognitive impairment’’, we used the criteria
proposed by Amato et al. (2010), a failure in at least two BRB-N
tests, with scores at least 1.5 SD below the scores of HC. Thus,
if a patient had zero or one BRB-N test score at least 1.5 SD
below that of HC the patient was considered to have no cognitive
impairment. If a patient had two or more BRB-N test scores at
least 1.5 SD below that of HC, the patient was considered to
have cognitive impairment. In order to differentiate the degree of
severity of deficits, if a patient had two BRB-N test scores below
that of HC, the patient was considered to have a mild degree of
cognitive impairment. If a patient had three BRB-N test scores
below that of HC, the patient was considered to have moderate
cognitive impairment. Finally, if a patient had four or more BRB-
N test scores below that of HC, the patient was considered to have
severe cognitive impairment.
Statistical Analyses
Statistical analyses were performed using Stata (StataCorp.)
version 13. Parametric tests were used due to the large
sample sizes and because graphical exploration of the data
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indicated an acceptable distribution of the variables of interest.
Statistical analyses were as follows: firstly, the comparison of
the two groups (patients and controls) was performed via
a series of t-tests for independent samples by considering
demographic and clinical variables: p-values were adjusted
for multiple comparisons using the false-discovery rate (FDR)
approach. Secondly, we investigated the presence and the
degree of cognitive impairment in our sample of patients
with MS at the three assessment points (e.g., T0, T1 and
T2). Thirdly, in order to investigate the longitudinal effect on
neuropsychological performances, univariate and multivariate
linear mixed models (LMM) with random intercept (function
Mixed in Stata, v.13) were performed for each scale investigated.
Particularly, the interaction term ‘‘group× time’’ was introduced
into the model to test statistically whether the trajectories
over time were significantly different in MS patients and
healthy subjects. Furthermore, in order to investigate the
longitudinal neuropsychological profile of patients with different
courses of the disease, MS patients were also divided into
two sub-groups, depending on their disease course (RR-
MS, and prog-MS, respectively). LMMs were performed in
the same manner to investigate differences across these sub-
groups. In this last analysis, p-values were adjusted for multiple
comparisons using the FDR control approach. To correct
the univariate trajectories for possible confounders, patients’
socio-demographic variables (e.g., age, gender, education,
job status) found to be significantly associated with the
single neuropsychological scales were introduced in a final
multivariable model. Furthermore, the addition of a random
slope into the LMMs was also considered by comparing model
goodness of fit with and without the random slope entered
based on Akaike Information Criterion (AIC) and Bayesian
Information Criterion (BIC). A p-value lower than 0.05 was
considered statistically significant.
RESULTS
At the baseline, the two groups of participants were well matched
for gender, pre-morbid IQ and years of formal education,
whereas a difference in age was detected, with patients being
younger than HC.
Neuropsychiatric Measures
Five patients and three HC refused to complete the HADS. One
patient and five HC did not complete the FSS. All of the other
scores have been collected and used in the present analyses.
The two groups of participants differed in HADS-anxiety
(t(615) = 2.522, p < 0.05) and HADS-depression (t(615) = 4.740,
p < 0.01). In addition, they also differed in the level of fatigue
(t(574) = 10.654, p < 0.01), in keeping with previously published
studies. Table 1 reports the demographic and neuropsychiatric
variables of interest.
Neuropsychological Measures
As a typical issue in longitudinal studies, not all the participants
were available at the two scheduled follow-ups (1 and 2 years,
TABLE 1 | Demographic and clinical variables of patients with multiple
sclerosis (MS) and healthy controls (HCs) at baseline.
Variable MS patients Healthy controls t-test p-value∗
mean (SD) mean (SD) (df) or χ2
(n = 322) (n = 303)
Participants’
characteristics
Age in years 41.98 (11.37) 44.89 (11.64) 3.161 (623) 0.0032
Gender (M:F) 97.225 93.210 χ2 = 0.024 0.88
Education in years 12.86 (3.61) 13.18 (3.94) 1.064 (623) 0.33
IQ 111.78 (6.50) 112.37 (6.53) 1.121 (623) 0.33
Duration of illness 9.16 (7.13) – –
in years
Clinical measures
HADS–anxiety 6.67 (3.55) 5.96 (3.42) 2.522 (615) 0.019
HADS–depression 5.70 (3.91) 4.36 (3.11) 4.740 (615) <0.001
HADS–total 12.37 (6.72) 10.32 (5.87) 4.047 (615) <0.001
FSS 35.74 (15.18) 24.25 (11.52) 10.654 (617) <0.001
EDSS 2.37 (1.90) – –
*, Adjusted for multiple comparisons with false-discovery rate (FDR) approach;
df, degrees of freedom; EDSS, Expanded Disability Status Scale; FSS, Fatigue
Severity Scale; HADS, Hospital Anxiety and Depression Scale; IQ, Intelligence
Quotient.
respectively). Figure 1 reports a detailed indication of the
participants available at each assessment point.
Firstly, we investigated the presence and the degree of
cognitive impairment in our sample of patients with MS at
the three assessment points (e.g., T0, T1 and T2). Table 2
reports the proportion of MS patients cognitively impaired
at the three assessment stages, and their degree of cognitive
impairment.
Secondly, we were interested in investigating the longitudinal
effect on participants’ performance on the BRB-N tests.
As expected, in all of the measures a significant effect
of ‘‘group’’ was detected, as performances of patients and
HC significantly differed in all of the BRB-N tests with
patients getting lower scores than controls. However, for
the aim of our study, we were mainly curious about
the interaction between ‘‘group’’ and ‘‘time’’: interestingly,
the interaction between the two factors was statistically
significant for the SDMT (p = 0.044; adjusted for baseline age),
the PASAT-2 (p = 0.011; adjusted for baseline age) and the
WLG (p < 0.001; adjusted for baseline age), and approached
statistical significance for PASAT-3 (p = 0.05; adjusted for
baseline age). Table 3 reports the details of participants’
performance at each assessment point, showing a general modest
improvement at the 1-year follow-up, and a significant decay
of performance between the two follow-ups on the tests just
mentioned.
Figure 2 reports graphically the longitudinal performance of
the two groups of participants on the PASAT-3 at the three
assessment points.
Besides, in order to investigate the longitudinal
neuropsychological profile of patients with different course
of the disease, we considered three groups of participants:
HC, patients with a relapsing-remitting course of MS (i.e.,
RR-MS), and patients with a progressive course of the disease
Frontiers in Human Neuroscience | www.frontiersin.org 4 June 2016 | Volume 10 | Article 282
Borghi et al. Neuropsychological Decline in Multiple Sclerosis
FIGURE 1 | Number of participants (Multiple Sclerosis (MS) patients and healthy controls (HCs)) at each assessment point.
TABLE 2 | Proportion of MS patients cognitively impaired at the three assessment points, and their degree of cognitive impairment.
Cognitively impaired? Degree of cognitive impairment
Assessment point NO YES Mild Moderate Severe
T0: Baseline (N = 322) N = 213 (66.1%) N = 109 (33.9%) N = 35 (32.1%) N = 28 (25.7%) N = 46 (42.2%)
T1: After 1 year (N = 293) N = 178 (60.8%) N = 115 (39.2%) N = 52 (45.2%) N = 24 (20.9%) N = 39 (33.9%)
T2: After 2 years (N = 230) N = 154 (67.0%) N = 76 (33.0%) N = 25 (32.9%) N = 19 (25.0%) N = 32 (42.1%)
(i.e., prog-MS). Again, we were primarily curious about the
interaction between ‘‘group’’ and ‘‘time’’. The interaction
between the two factors was statistically significant for
PASAT-3 (p = 0.017), with a significant difference between
HC and the progressive group of patients (p = 0.016),
whereas the differences between the two groups of patients
(p = 0.057) and between RRMS and HC (p = 0.21) did not
reach statistical significance. Particularly PASAT-3 values for
progressive patients at time 3 reverted to baseline values after an
increase at time 2. Similar results were observed for PASAT-2
(p = 0.0026), with progressive MS significantly different both
from HC (p = 0.0072) and RRMS (p = 0.033) and with
the difference between relapsing MS and HC approaching
statistical significance (p = 0.05). Also for the score of
WLG, a significant difference among groups (p = 0.0022)
was observed, with a significant difference between HC
and RRMS patients (p < 0.001) but not with progressive
MS (p = 0.51) and between relapsing and progressive MS
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TABLE 3 | Neuropsychological measures in MS patients and healthy controls (HC) at each assessment point (for TIB-errors, lower scores mean better
performance; for all of the other tests, higher scores mean better performance).
Variable T0 Delta T1-T0a Delta T2-T0a Delta T2-T1a p-value interaction
MS HC MS HC MS HC MS HC time × group∧
TIB–IQ 111.78 (6.50) – –
112.37 (6.53)
TIB–errors 4.53 (5.29) – –
4.14 (5.01)
SRT–LTS 38.35 (14.72)∗ 3.99 (0.77) 4.65 (0.80) 0.66 (0.81) 0.96
[range 0–72] 44.34 (13.12) 4.19 (0.74) 4.51 (0.81) 0.31 (0.82)
SRT–CLTR 28.12 (14.49)∗ 4.40 (0.85) 5.06 (0.89) 0.66 (0.93) 0.6
[range 0–72] 34.72 (14.63) 3.80 (0.87) 5.77 (0.88) 1.97 (0.92)
SPART 18.48 (5.50)∗ 2.21 (0.30) 1.61 (0.32) −0.60 (0.33) 0.73
[range 0–30] 19.96 (4.61) 1.90 (0.31) 1.32 (0.32) −0.58 (0.32)
SDMT 46.96 (13.10)∗ 2.21 (0.47) 0.21 (0.48) −2.00 (0.45) 0.049
[range 0–110] 52.17 (10.42) 1.85 (0.48) 1.33 (0.47) −0.52 (0.45)
PASAT–3 39.70 (12.62)∗ 3.31 (0.53) 2.58 (0.59) −0.73 (0.57) 0.05
[range 0–60] 41.86 (10.82) 3.03 (0.54) 4.13 (0.56) 1.10 (0.55)
PASAT–2 27.37 (10.42)∗ 2.42 (0.52) 2.81 (0.61) 0.39 (0.58) 0.011
[range 0–60] 30.94 (10.54) 2.26 (0.52) 4.90 (0.57) 2.64 (0.55)
SRT–D 7.44 (2.54)∗ 0.49 (0.11) 0.48 (0.12) −0.01 (0.12) 0.43
[range 0–12] 8.29 (2.22) 0.49 (0.11) 0.68 (0.12) 0.19 (0.12)
SPART–D 6.51 (2.30)∗ 0.60 (0.13) 0.46 (0.14) −0.14 (0.14) 0.3
[range 0–10] 6.90 (2.02) 0.86 (0.13) 0.49 (0.14) −0.37 (0.14)
WLG 22.29 (5.70)∗ 2.66 (0.38) 0.53 (0.34) −2.13 (0.41) < 0.001
23.28 (5.50) 4.08 (0.39) 2.37 (0.33) −1.71 (0.41)
a, results reported as delta coefficient (standard error); ∧obtained from linear mixed model; PASAT, Paced Auditory Serial Addition Test; SDMT, Symbol Digit Modalities Test;
SPART, Spatial Recall Test; SPART–D, Spatial Recall Test-Delayed; SRT–CLTR, Selective Reminding Test-Consistent Long Term Retrieval; SRT–D, Selective Reminding
Test-Delayed; SRT–LTS, Selective Reminding test-Long Term Storage; TIB–errors, Brief Intelligence Test-Errors; TIB–IQ, Brief Intelligence Test–Intelligence Quotient;
WAIS–Voc, WAIS Vocabulary; WLG, Word List Generation.
(p = 0.81). Figure 3 reports graphically the longitudinal
performance of the three groups of participants on the PASAT-2
at the three assessment points. To conclude, the correlation
between HADS-anxiety and SDMT, PASAT-3 and PASAT-2
were low (−0.22, −0.18, −0.12 respectively) and similarly
for HADS-depression (−0.23, −0.17, −0.14 respectively).
Slight-moderate negative correlations ranging between −0.32
(PASAT-2) and −0.45 (SDMT) were observed with EDSS at
baseline.
Lastly, we were still interested in investigating differences
in the longitudinal neuropsychological profile between MS
patients already cognitively impaired at baseline and MS
patients cognitively preserved at the beginning of the study.
Considering SDMT, the mean change score over 1 year was
2.51 (standard deviation (SD): 8.3; median:3 [IQR: −2–7]) for
198 no cognitively impaired patients at baseline and with no
missing assessment at 1-year while was 1.24 (SD: 10.4; median:1
[IQR:−2–4]) for the 94 cognitively impaired patients at baseline
and with no missing observation at 1 year, with no significant
difference between the two groups (p = 0.064). At the 2-year
follow-up, 157 not cognitively impaired patients showed a
change from baseline of 0.67 (SD: 7.6; median: 1 [IQR: −5–5])
compared with a delta of −1.2 (SD: 10.4; median: −0.5 [IQR:
−5.5–4]) in 72 cognitively impaired patients. The difference
did not reach statistical significance (p = 0.13). For PASAT-
2, at 1 year cognitively and not cognitively impaired patients
performed similarly (3 vs. 2; p = 0.28) and maintained a similar
change also at 2 years (2.5 vs. 3; p = 0.63). On PASAT-3,
cognitively impaired patients (n = 86) improved more (mean:
4.56; SD: 10.5; median:4 [IQR: −1–11]) as compared with no
cognitively impaired patients (n = 190; mean: 2.47; SD: 8.8;
median: 2 [IQR: −2–6]), with a difference that approached
the statistical significance (p = 0.087). At 2 years however
while not cognitively impaired patients maintained a similar
change (n = 152; mean: 2.3; SD: 10), cognitively impaired
patients decreased their values (n = 56; mean: 3.4; SD:13.7)
with no significant difference between them (p = 0.53). Lastly,
for WLG significant differences were observed at 1 year: while
cognitively impaired patients increased slightly (mean: 1.4;
SD: 6), patients without baseline impairments performed better
(mean: 3.1; SD: 6.6) with a significant difference between them
(p = 0.048). No significant differences at 2 years (p = 0.90) were
detected.
DISCUSSION
Cognitive deficits typically characterize the neuropsychological
profile of patients affected by MS. Robust evidence has shown
that a proportion of patients with MS present with some degree
of cognitive impairment (Amato et al., 2010; Borghi et al., 2013),
urgently calling for the implementation of a neuropsychological
assessment as part of routine clinical practice. However, to
date studies have not focused on the evolution over time of
neuropsychological abilities in large groups of MS patients, as
compared to large groups of HC. Besides, at this point in time
very little is known about the changes of neuropsychological
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FIGURE 2 | Longitudinal performance of the two groups of participants on the PASAT-3 at the three assessment points.
profile in progressive MS patients, as compared to relapsing-
remitting MS patients and HC. In our study, the construct of
‘‘cognitive impairment’’ has been defined operatively as having
two or more BRB-N tests with scores at least 1.5 SD below
the scores of HC at the corresponding assessment point (e.g.,
T0, T1, and T2), as widely used in previous studies (Amato
et al., 2010; Stankiewicz et al., 2011; Borghi et al., 2013).
In keeping with published literature, a significant proportion
of MS patients (i.e., 33.9%) presented with some degree of
cognitive impairment at the time of recruitment, as compared
to HC. At the 1-year follow-up, the proportion of patients
with some degree of cognitive impairment increased (39.2%),
whereas at the 2-year follow-up it decreased to the baseline
value (33.0%). Considering the most critical neuropsychological
tests (SDMT, PASAT-2, PASAT-3 and WLG), there was not
a significantly different decline over the course of the study
between MS patients already compromised at the baseline,
and cognitively preserved MS patients (only WLG showed a
significant difference). A possible explanation for this is that the
time-frame of our study (2 years) be too short to detect a more
significant decay of cognitive impairment in patients already
impaired at baseline, as compared to patients not presenting
with cognitive deficits. Another explanation may be that it is still
possible that patients presenting with cognitive impairment at
the beginning of the study be more likely to show learning effect
than patients not cognitively impaired and then already good at
baseline. However, future studies should address this important
point.
As we had 29 patients who did not show up at the first
follow-up, and an additional 63 patients who did not accept
to participate in the second follow-up, a possible explanation
of this trend in the proportion of cognitively impaired patients
at the three assessment points was that patients more severely
affected may have refused to continue the study, allowing
us to monitor only patients with a less severe degree of
impairment: then, it may be possible that our study has
underestimated the decline of cognitive abilities in MS over time.
We tested this hypothesis: frequency of cognitively impaired
patients who dropped-out at 1-year was 14/109 (12.8%) vs.
14/213 (6.6%) in not cognitively impaired. This difference
approached statistical significance (p = 0.059). At 2-year follow-
up, 36/109 (33%) impaired patients and 55/213 (25.8%) not
impaired patients were lost to follow-up, with no statistical
significance (p = 0.17). Thus, even if the proportion of patients
who dropped out was different in the two groups in absolute
values, the small proportion of drop-outs which characterized
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FIGURE 3 | Longitudinal performance of the three groups of participants on the PASAT-2 at the three assessment points.
our study did not allow us to detect a statistically significant
difference.
The two groups of participants (MS patients and HC)
were well matched for pre-morbid IQ, education, and gender.
Levels of both anxiety and depression in the two groups
were below the clinical borderline range of values, allowing
us to rule out on clinical grounds the presence of significant
neuropsychiatric symptoms. The two groups still differed in
terms of fatigue. Regarding their neuropsychological profile, at
baseline patients had significantly lower scores than controls
on all of the measures administered, with the exception of
the TIB-IQ. At the two scheduled follow-ups, patients got
significantly lower scores than controls on all of the measures
administered, with the exception of the SRT-CLTR at the 2-year
follow-up: this measure detects consistency of the recovery
in long-term memory, and it is possible that this specific
cognitive ability be less influenced by the progression of MS as
compared to others (in fact, this was the only case in which
patients got a higher score in absolute value than controls).
However, future studies should specifically address this issue
more deeply.
The primary aim of our study was to investigate changes
in neuropsychological abilities in MS patients over time, as
compared to controls. Thus, a LMM was run by considering
participants’ performance on each test of the BRB-N at the
three assessment points (i.e., T0, T1 and T2) as the within-
subjects variable, and ‘‘group’’ (i.e., MS patients and HC) as
the between-subjects factor: in all of the measures a significant
effect of ‘‘group’’ was detected, as the performance of patients
and HC significantly differed in all of the BRB-N tests with
patients getting lower scores than controls. However, we were
mainly curious about the interaction between ‘‘group’’ and
‘‘time’’. Interestingly, the interaction between these two factors
was statistically significant for the SDMT and the PASAT-2
(that measure mainly attention, working memory, and speed
of information processing), and the WLG (that measures
semantic verbal fluency), whereas for the PASAT-3 it approached
statistical significance. Regarding patients’ performance on
the SDMT and PASAT, it is now well established that MS
particularly affects the cognitive abilities tapped by these
tasks (Chiaravalloti and DeLuca, 2008): our results further
extend this consideration, by suggesting not only that these
abilities are more vulnerable than others to the presence
of MS, but also that they are likely to be more sensitive
than others to the progression of the disease, as compared
to HC. In keeping with this, in the near future it will
be extremely important to focus on pilot studies aiming
at training such abilities in MS patients (see for example
Hancock et al., 2015), in order to contrast their decay over
time.
Frontiers in Human Neuroscience | www.frontiersin.org 8 June 2016 | Volume 10 | Article 282
Borghi et al. Neuropsychological Decline in Multiple Sclerosis
In addition, we were still interested in studying possible
differences in the neuropsychological decline over time of
subgroups of patients affected by different course of the disease
(relapsing-remitting, RR-MS, vs. progressive course of MS,
prog-MS). Thus, for further statistical analyses we considered
three groups of participants: HC, patients with a RR-MS, and
patients with prog-MS. The interaction between these two
factors was statistically significant for the PASAT-3 and the
PASAT-2, and the WLG. In keeping with previous literature,
patients affected by progressive MS generally got lower scores
on neuropsychological tests as compared to patients affected
by the relapsing-remitting form of the disease. Regarding
the first test (PASAT-3), both the two groups of patients
differed significantly from controls, but the comparison of
the performance in the two groups of patients did not
reach a statistically significant difference. Along a similar
vein, regarding the PASAT-2 both the two groups of patients
differed significantly from controls, and the comparison of
the performance in the two groups of patients approached
significance. In our view, the main reason why we were not
able to detect a statistically different performance on these tasks
in the two groups of patients pertains to the small sample
size of the group of patients affected by the progressive form
of MS, as compared to the other groups: at the beginning
we recruited N = 36 prog-MS patients, that remained 29
at the first follow-up, and only 21 at the last scheduled
neuropsychological assessment. Thus, even if from a graphical
point of view there was a clear tendency of prog-MS patients
in getting significantly lower scores than RR-patients in most
of the measures over time, it is reasonable to assume that
from a statistical standpoint the reduced sample size could
have played a role in masking the real entity of such
differences.
Lastly, it is still relevant to discuss the pattern of results
related to patients’ performance on theWLG task. Verbal fluency
deficits can characterize the neuropsychological profile of MS
(Vlaar and Wade, 2003; Henry and Beatty, 2006), and it has
been recently shown that this cognitive deficit seems to be
more frequently associated with the progressive form of the
disease (Connick et al., 2012). In keeping with this, in our
subgroup of prog-MS patients we were able to demonstrate
not only that verbal fluency deficits were present in their
neuropsychological profile, but also that this ability appeared
to decay significantly over time. However, as previously said,
due to the small sample size any conclusion about prog-MS
has to be taken with caution, and necessarily need further
investigations.
The present study presents some strengths. Firstly, to the
best of our knowledge, this is one of the first studies that
followed longitudinally large groups of both MS patients and
well-matched HC, in order to detect and monitor participants’
neuropsychological profile over time: as a result, the large
sample sizes allowed us to obtain reliable evidence about
the presence and evolution of cognitive impairment in MS.
Previous studies have already included large group of patients
(e.g., Van Schependom et al., 2015) or monitored patients
over longer period of time (e.g., Piras et al., 2003; Denney
et al., 2008), but a strength of our study was the inclusion
of large groups of patients and HC, both monitored over
2 years from a neuropsychological point of view. Secondly,
only very few patients and HC did not perform all of the
tests administered, and above all we were able to maintain
into the study the vast majority of participants until the
planned 2-year follow-up: thus, we can consider our results
as mirroring the entire the samples recruited and not only a
small proportion of them. In addition, to minimize practice
effects, two parallel versions of the BRB-N were used and were
alternatively administered during follow-ups: in doing so, the
same version of the neuropsychological battery was repeated
by each participant only after 2 years. Lastly, considering
not only MS patients as a whole but also splitting the
MS patients into two groups according to the type of MS
(i.e., RR-MS, and prog-MS) allowed us to investigate the
neuropsychological profile associated with the very relevant
clinical factor represented by the course of the disease, that
should always be taken into account also when dealing with
the assessment and rehabilitation of cognitive deficits in
MS.
The study also presents some limitations. Firstly, although
in the BRB-N the executive functions are underrepresented,
due to time constraints we did not administer adjunctive tests
of executive functions. Thus, it is not possible to completely
rule out the possibility that patients presenting with a mild
degree of executive dysfunction may have not been identified
as ‘‘cognitively impaired’’ by our neuropsychological assessment,
leading to an underestimation of their actual degree of cognitive
deficits. Secondly, our final sample of prog-MS patients was
relatively small, as compared to RR-MS patients and HC: thus,
generalization of conclusions to patients affected by this specific
sub-type of disease has to be made with caution. Lastly, we
did not investigate the construct of cognitive reserve in our
sample, which posits that genetic and environmental factors
protect against cognitive decline in the face of neurological
disorders, likely due to greater capacity and efficiency of neural
circuits. As a result, there are likely to be individual differences
in terms of the cognitive changes associated with MS (Stern,
2002).
To conclude, our evidence corroborated on a very large scale
that neuropsychological deficits are a common clinical feature
of MS that should be carefully screened for at the very early
stages of the condition, and above all seriously monitored over
time. For the first time it has been shown on a large scale
that the cognitive abilities typically compromised at the early
stages of MS (attention, working memory, speed of information
processing, and verbal fluency) are also more vulnerable than
others to the progression of the disease as compared to HC,
urgently calling for the identification of effective rehabilitation
treatments able to counteract at least partially their decline over
time.
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